➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Boehringer Ingelheim
Medtronic
McKinsey
Express Scripts

Last Updated: February 25, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NARATRIPTAN

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Naratriptan

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00282165 Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order Terminated FPC De Kijvelanden, Poortugaal Phase 4 2006-11-01 In a double blind randomized clinical trial with cross-over design, treatment using naratriptan will be compared to placebo within a group of 30 convicts with psychiatric disorders such as psychosis or psychopathy with repeated aggressive outbursts resistant to conventional psychopharmacologic and other psychotherapeutic treatment. Hypothesis is that addition of naratriptan to the individual treatment regime reduces aggression -and improves general outcome- as compared to addition of placebo and is well tolerated in this group and under these conditions.
NCT00282165 Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order Terminated UMC Utrecht Phase 4 2006-11-01 In a double blind randomized clinical trial with cross-over design, treatment using naratriptan will be compared to placebo within a group of 30 convicts with psychiatric disorders such as psychosis or psychopathy with repeated aggressive outbursts resistant to conventional psychopharmacologic and other psychotherapeutic treatment. Hypothesis is that addition of naratriptan to the individual treatment regime reduces aggression -and improves general outcome- as compared to addition of placebo and is well tolerated in this group and under these conditions.
NCT00487578 Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction Terminated Clinvest Phase 4 2006-10-01 The purpose of this study is to determine whether naratriptan, a medication approved for treatment of migraine, is effective in the treatment of post traumatic headache associated with cognitive dysfunction.
NCT00487578 Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction Terminated GlaxoSmithKline Phase 4 2006-10-01 The purpose of this study is to determine whether naratriptan, a medication approved for treatment of migraine, is effective in the treatment of post traumatic headache associated with cognitive dysfunction.
NCT00487578 Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction Terminated Cady, Roger, M.D. Phase 4 2006-10-01 The purpose of this study is to determine whether naratriptan, a medication approved for treatment of migraine, is effective in the treatment of post traumatic headache associated with cognitive dysfunction.
NCT01059604 Sumatriptan and Naratriptan Pregnancy Registry Completed GlaxoSmithKline N/A 2001-12-01 Anti-migraine drugs, including triptans, are not indicated for use in pregnancy. However, the peak prevalence of migraine is in women of childbearing age. This, coupled with the sporadic nature of migraine attacks and high rates of unplanned pregnancies, makes unintentional exposure to anti-migraine medications during pregnancy likely. Prior to an anti-migraine medication being marketed there are few data available on drug safety in pregnancy: data from animal models may not translate directly to humans and pregnant women are routinely excluded from clinical trials. The Sumatriptan Pregnancy Registry was established by GlaxoSmithKline (GSK) in 1996 to monitor the safety of sumatriptan during pregnancy. It was combined with the Naratriptan Pregnancy Registry in 2001 and data collection on the sumatriptan-naproxen combination (Treximet) began in 2008.
NCT01161654 Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed Conditions Completed Roxane Laboratories N/A 2007-08-01 The objective of this study was to prove the bioequivalence of Naratriptan Hydrochloride Tablet under fed conditions.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Naratriptan

Condition Name

Condition Name for Naratriptan
Intervention Trials
Migraine 4
Migraine Disorders 3
Headache 2
Intermittent Explosive Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Naratriptan
Intervention Trials
Migraine Disorders 6
Headache 3
Personality Disorders 1
Mental Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Naratriptan

Trials by Country

Trials by Country for Naratriptan
Location Trials
United States 5
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Naratriptan
Location Trials
Washington 2
Texas 1
North Carolina 1
Missouri 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Naratriptan

Clinical Trial Phase

Clinical Trial Phase for Naratriptan
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Naratriptan
Clinical Trial Phase Trials
Completed 5
Terminated 2
Withdrawn 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Naratriptan

Sponsor Name

Sponsor Name for Naratriptan
Sponsor Trials
GlaxoSmithKline 4
Roxane Laboratories 2
Ache Laboratorios Farmaceuticos S.A. 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Naratriptan
Sponsor Trials
Industry 9
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
McKesson
Baxter
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.